WallStreetZenWallStreetZen

NASDAQ: SAVA
Cassava Sciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for SAVA

Based on 1 analyst offering 12 month price targets for Cassava Sciences Inc

Min Forecast
$8.00+173.04%
Avg Forecast
$8.00+173.04%
Max Forecast
$8.00+173.04%

Should I buy or sell SAVA stock?

Based on 1 analyst offering ratings for Cassava Sciences Inc.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although SAVA's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates SAVA as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their SAVA stock forecasts and price targets.

SAVA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-10-06

1 of 1

Forecast return on equity

Is SAVA forecast to generate an efficient return?

Company
N/A
Industry
248.15%
Market
227.73%

Forecast return on assets

Is SAVA forecast to generate an efficient return on assets?

Company
N/A
Industry
88.69%

SAVA earnings per share forecast

What is SAVA's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$1.97
Avg 2 year Forecast
-$1.24
Avg 3 year Forecast
$9.18

SAVA revenue forecast

What is SAVA's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

SAVA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SAVA$2.93$8.00+173.04%Strong Buy
ELTX$8.15$13.00+59.51%Buy
CGEN$1.49N/AN/A
GANX$3.86$7.50+94.30%Strong Buy
GLSI$10.40N/AN/A
View Top Biotech Stocks

Cassava Sciences Stock Forecast FAQ

Is Cassava Sciences Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: SAVA) stock is to Strong Buy SAVA stock.

Out of 1 analyst, 1 (100%) are recommending SAVA as a Strong Buy, 0 (0%) are recommending SAVA as a Buy, 0 (0%) are recommending SAVA as a Hold, 0 (0%) are recommending SAVA as a Sell, and 0 (0%) are recommending SAVA as a Strong Sell.

If you're new to stock investing, here's how to buy Cassava Sciences stock.

What is SAVA's earnings growth forecast for 2025-2027?

(NASDAQ: SAVA) Cassava Sciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.2%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.67%.

Cassava Sciences's earnings in 2025 is -$106,031,000.On average, 4 Wall Street analysts forecast SAVA's earnings for 2025 to be -$95,098,924, with the lowest SAVA earnings forecast at -$91,369,554, and the highest SAVA earnings forecast at -$97,895,951. On average, 3 Wall Street analysts forecast SAVA's earnings for 2026 to be -$60,114,346, with the lowest SAVA earnings forecast at -$57,756,920, and the highest SAVA earnings forecast at -$61,882,415.

In 2027, SAVA is forecast to generate $443,466,485 in earnings, with the lowest earnings forecast at $426,075,643 and the highest earnings forecast at $456,509,617.

What is SAVA's revenue growth forecast for 2025-2027?

(NASDAQ: SAVA) Cassava Sciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 100.07%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.5%.

Cassava Sciences's revenue in 2025 is $0.On average, 4 Wall Street analysts forecast SAVA's revenue for 2025 to be $0, with the lowest SAVA revenue forecast at $0, and the highest SAVA revenue forecast at $0. On average, 3 Wall Street analysts forecast SAVA's revenue for 2026 to be $0, with the lowest SAVA revenue forecast at $0, and the highest SAVA revenue forecast at $0.

In 2027, SAVA is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is SAVA's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: SAVA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 88.69%.

What is SAVA's Price Target?

According to 1 Wall Street analyst that have issued a 1 year SAVA price target, the average SAVA price target is $8.00, with the highest SAVA stock price forecast at $8.00 and the lowest SAVA stock price forecast at $8.00.

The Wall Street analyst predicted that Cassava Sciences's share price could reach $8.00 by Oct 6, 2026. The average Cassava Sciences stock price prediction forecasts a potential upside of 173.04% from the current SAVA share price of $2.93.

What is SAVA's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: SAVA) Cassava Sciences's current Earnings Per Share (EPS) is -$2.22. On average, analysts forecast that SAVA's EPS will be -$1.97 for 2025, with the lowest EPS forecast at -$1.89, and the highest EPS forecast at -$2.03. On average, analysts forecast that SAVA's EPS will be -$1.24 for 2026, with the lowest EPS forecast at -$1.20, and the highest EPS forecast at -$1.28. In 2027, SAVA's EPS is forecast to hit $9.18 (min: $8.82, max: $9.45).

What is SAVA's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: SAVA) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.